Search hospitals > California > Anaheim
Advanced Research Center Inc.
Claim this profileAnaheim, California 92805
Global Leader in Schizophrenia
Global Leader in Depression
Conducts research for Alzheimer's Disease
Conducts research for Major Depressive Disorder
Conducts research for Constipation
125 reported clinical trials
6 medical researchers
Summary
Advanced Research Center Inc. is a medical facility located in Anaheim, California. This center is recognized for care of Schizophrenia, Depression, Alzheimer's Disease, Major Depressive Disorder, Constipation and other specialties. Advanced Research Center Inc. is involved with conducting 125 clinical trials across 71 conditions. There are 6 research doctors associated with this hospital, such as Daniel Johnson, MD, Austina Cho, MD, Rennan Quijano, MD, and Johnson.Top PIs
Daniel Johnson, MDOchsner Clinic Foundation6 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
10 reported clinical trials
25 drugs studied
Austina Cho, MDAdvanced Research Center, Inc.1 year of reported clinical research
Studies Schizophrenia
Studies Obsessive-Compulsive Disorder
6 reported clinical trials
7 drugs studied
Rennan Quijano, MDAdvanced Research Center (ARC)1 year of reported clinical research
Studies Attention Deficit Hyperactivity Disorder (ADHD)
Studies Constipation
4 reported clinical trials
4 drugs studied
JohnsonAdvanced Research Center2 years of reported clinical research
Studies Cardiovascular Disease
Studies Atherosclerosis
1 reported clinical trial
2 drugs studied
Clinical Trials running at Advanced Research Center Inc.
Alzheimer's Disease
Depression
Migraine
Dementia
Bipolar Disorder
Constipation
COVID-19
Coronavirus
Alzheimer's Dementia
Autism Spectrum Disorder
AVP-786
for Agitation in Alzheimer's Disease
This study is evaluating whether a drug may help reduce the risk of heart attack and stroke in individuals with heart disease.
Recruiting2 awards Phase 37 criteria
Masupirdine
for Agitation in Alzheimer's Disease
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Recruiting1 award Phase 32 criteria
ABBV-916
for Early Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-916 is in treating early AD. Adverse events, change in disease activity, and how ABBV-916 moves through body of participants will be assessed. ABBV-916 is an investigational drug being developed for the treatment of early AD. This study is conducted in 2 stages. Stage A is a multiple ascending dose study. There is a 1 in 4 chance that participants are assigned to receive placebo. Stage B is a proof-of-concept study. In Stage B, there is a 1 in 5 chance that participants will be assigned to receive placebo. The first 6 months of this study are "double-blind," which means that neither the trial participant nor the study doctors know which treatments will be given. This will be followed by a 2-year extension period in which all participants will receive ABBV-916. Approximately 195 participants aged 50-90 years will be enrolled in about 90 sites across the world. Participants will receive intravenous (IV) doses of ABBV-916 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for an additional 16 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, magnetic resonance imaging (MRI), blood tests, checking for side effects and completing questionnaires.
Recruiting0 awards Phase 26 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Advanced Research Center Inc.?
Advanced Research Center Inc. is a medical facility located in Anaheim, California. This center is recognized for care of Schizophrenia, Depression, Alzheimer's Disease, Major Depressive Disorder, Constipation and other specialties. Advanced Research Center Inc. is involved with conducting 125 clinical trials across 71 conditions. There are 6 research doctors associated with this hospital, such as Daniel Johnson, MD, Austina Cho, MD, Rennan Quijano, MD, and Johnson.